Rachel Abbott becomes CEO at Pan Cancer T

Thursday 25 May 2023
Pan Cancer T BV
Appointee name
Rachel Abbott


Rachel Abbott, an experienced biotech executive, has been named chief executive of Netherlands-based Pan Cancer T BV to manage development of the company’s help the company’s T cell receptor T cell therapies for cancer. She was previously chief scientific officer and succeeds the outgoing CEO and co-founder Katrien Reynders-Frederix. Dr Abbott was previously head of TCR pipeline and dark antigen research at Enara Bio Ltd where she worked on the discovery and validation of dark antigens which are that part of the human genome which is usually not expressed as protein. Prior to this she was head of pipeline cell biology at Adaptimmune Plc.

Dr Abbott holds a DPhil and an MBiochem in molecular and cellular biochemistry, both from the University of Oxford, UK.

Pan Cancer T BV announced the appointment on 12 May 2023.

Copyright 2023 Evernow Publishing Ltd